Evidence map›Paper›PMID 27449288›Full record

SynthesisOncotarget2016

Two common functional catalase gene polymorphisms (rs1001179 and rs794316) and cancer susceptibility: evidence from 14,942 cancer cases and 43,285 controls.

Kang Liu, Xinghan Liu, Meng Wang, Xijing Wang, Huafeng Kang, Shuai Lin, Pengtao Yang, Cong Dai, Peng Xu, Shanli Li and 1 more

Open access · diamondAbstract readMeta-Analysis
In one paragraph

Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Association of variations in theFrontiers in pharmacology · 2023
    Article
  9. Article
  10. Article
  11. An investigation of the relation between catalaseArchives of medical science : AMS · 2021
    Article
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Kang LiuDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Xinghan LiuDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Meng WangDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Xijing WangDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Huafeng KangDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Shuai LinDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Pengtao YangDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Cong DaiDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Peng XuDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Shanli LiDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Zhijun DaiDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Second Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies have focused on the associations of catalase polymorphisms with various types of cancer, including cervical and prostate cancers. However, the results were inconsistent. To obtain a more reliable conclusion, we evaluated the relationship between the two common catalase gene polymorphisms (rs1001179 and rs794316) and cancer risk by a meta-analysis. Our meta-analysis included 37 published studies involving 14,942 cancer patients and 43,285 cancer-free controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the cancer risk. The results demonstrated that the rs1001179 polymorphism was associated with an increased cancer risk in the recessive and homozygote models (TT vs. CC: OR = 1.19, P = 0.01; TT vs. CT+CC: OR = 1.19, P <0.001). Furthermore, stratified analyses revealed a significant association between the rs1001179 polymorphism and prostate cancer in all models except the homozygote comparison. An association of the rs794316 polymorphism with cancer risk was detected in two genetic models (TT vs. AA: OR = 1.34, 95% CI = 1.03-1.74, P <0.001; TT vs. AT+AA: OR = 1.39, 95% CI = 1.09-1.77, P = 0.01). Additional well-designed studies with large samples should be performed to validate our results.

Indexed as

Genetic Predisposition to DiseasePolymorphism, Single NucleotideAllelesCase-Control StudiesCatalaseGenes, RecessiveGenotypeHomozygoteHumansNeoplasmsOdds RatioRisk FactorsCatalaseCAT protein, humancancercatalasemeta-analysispolymorphismsusceptibility

Identifiers

PMID27449288
PMCPMC5325339
OpenAlexW2462822213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.